Cenyx Biotech Inc.
- Biotech or pharma, therapeutic R&D
Clinical-stage nanozyme company, pioneering a first-in-human modality promising to become the next-generation anti-inflammatory medication for acute and chronic inflammatory diseases. Our lead candidate, CX213, has received FDA IND approval and ODD (Orphan Drug Designation) for SAH-induced inflammation and is entering Phase 1a in the US in June 2025. Our second pipeline, CX301, targeting AKI (acute kidney injury), is also advancing toward the clinic, with IND submission and approval expected in 2Q 2025.
)
)
)
){kind=logo}
)
){kind=logo}
){kind=logo}